SCHEDULE 13G
0001441449
XXXXXXXX
LIVE
Common Stock, par value $0.001
11/25/2024
0001720893
BioXcel Therapeutics, Inc.
09075P105
555 Long Wharf Drive
New Haven
CT
06511
Rule 13d-1(c)
Qatar Investment Authority
b
S3
2724075.00
0.00
2724075.00
0.00
2724075.00
N
5.20
OO
The numbers in rows 5, 7 and 9 represent 2,724,075 shares of Common Stock issuable to Q Boost Holding LLC, the Reporting Person's wholly-owned subsidiary (the "Subsidiary"), upon exercise of the Issuer warrant held by the Subsidiary.
The percentage of class in row 11 is calculated assuming 52,353,023 shares of common stock per share (the "Common Stock") are outstanding based on (i) 49,628,948 shares of Common Stock outstanding as of December 17, 2024 (such outstanding shares based on information provided to the Reporting Persons by the Issuer) and (ii) 2,724,075 shares of Common Stock issuable to the Subsidiary upon exercise of the Issuer warrant held by the Subsidiary.
BioXcel Therapeutics, Inc.
555 Long Wharf Drive, New Haven, CT 06511
Qatar Investment Authority (the "Reporting Person").
Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, State of Qatar.
Qatar
Y
2,724,075
5.20
2,724,075
0
2,724,075
0
Y
Y
N
See Exhibit 99.1
Y
Y
N
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Exhibit No. Description
99.1 Item 7 Information
99.2 Certificate of Incumbency
Qatar Investment Authority
/s/ Andrew Watkins
12/18/2024
**Evidence of authority to sign on behalf of Qatar Investment Authority is set forth in a Certificate of Incumbency, dated February 02, 2022, and included as Exhibit 99.2 hereto.